ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements
Kimia Biosciences Limited has scheduled a board meeting for November 13, 2026. The board will consider and approve the un-audited standalone financial results for the second quarter.
Kimia Biosciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Kimia Biosciences Limited announced the re-appointment of Mr. Sameer Goel as Executive Director and changes in designation for three other directors on the board.
Kimia Biosciences Ltd filed the proceedings of its 33rd Annual General Meeting held on September 28, 2026, where shareholders considered various ordinary and special resolutions.
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended March 31, 2026.
Kimia Biosciences Limited has submitted its notice for the 33rd Annual General Meeting scheduled for September 28, 2026, along with the Annual Report for FY 2025-26.
Kimia Biosciences' board meeting outcome includes director appointments, approval of the 33rd AGM notice, and increased borrowing/investment limits. The board also adopted the annual report.
Kimia Biosciences Ltd reported revenue from operations of ₹20.7 Cr (-12.3% YoY) and net profit of ₹0.4 Cr (-33.3% YoY) for Q1 FY27.
Kimia Biosciences will hold a board meeting on August 10, 2026, to consider and approve its standalone unaudited financial results for the quarter ending June 30, 2026.
Kimia Biosciences Limited announced changes to its auditor panel, including the cessation of one Secretarial Auditor and the appointment of new Internal, Cost, and Secretarial Auditors.
Kimia Biosciences appointed a new Cost Auditor, Internal Auditor, and Secretarial Auditor, while discontinuing the previous Secretarial Auditor following its recent Board Meeting.
Kimia Biosciences Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details holdings across promoter and public categories.
Kimia Biosciences Ltd reported revenue from operations of ₹27.2 Cr (-28.8% YoY) and net profit of ₹0.4 Cr (-80.0% YoY) for Q4 FY26.
Kimia Biosciences approved audited financial results for the year ended March 31, 2026. The board recorded a profit of ₹846.01 Lakhs on total income of ₹11,650.55 Lakhs.
Kimia Biosciences scheduled a board meeting for May 29, 2026, to approve audited financial results. The trading window remains closed until 48 hours after result declaration.
Kimia Biosciences Ltd announced several board changes following its April 18, 2026 meeting. Key updates include the cessation of Independent Director Ms. Richa Gupta and the appointment of Mr. Amulya Kumar Nayak as a Non-Executive Director. Additionally, the company modified the terms for Managing Director Mr. Sameer Goel to include retirement by rotation.
Kimia Biosciences Limited clarified to BSE that the recent movement in its share price is purely market-driven. The company confirmed it has no undisclosed price-sensitive information or pending announcements. It remains in compliance with SEBI listing regulations regarding material event disclosures.
Kimia Biosciences Limited announced a leadership overhaul including the appointment of Mr. Avinash Prabhat and Ms. Reema Goyal as Independent Directors for five years. Mr. Abhishek Kumar Pandey replaces Ms. Pallavi Garg as Company Secretary. These changes, following the tenure completion of Mr. Jagdeep Dhawan, aim to strengthen corporate governance and compliance frameworks.
Kimia Biosciences Limited announced the resignation of Pallavi Garg as Company Secretary and Compliance Officer, effective from the close of business hours on April 3, 2026. Ms. Garg is stepping down due to personal reasons. The company will place the resignation before the Board for formal acceptance.